# US 9,427,426 B2 · Indication of use of erdosteine as antidote in a large number of intoxications, especially in heavy metals like lead or mercury, and paracetamol

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,427,426 B2
- Document ID: US9427426B2
- Status: Granted
- Kind: B2
- Application number: 13/062,689
- Filed: 2009-08-13
- Published: 2011-07-14
- Granted: 2016-08-30
- Earliest claimed: 2008-09-08
- Assignees: Rafifarm S.R.L.
- Applicants: Marco Peretto; Cristina Sarbulescu; Victor Voicu
- Inventors: Marco Peretto; Cristina Sarbulescu; Victor Voicu
- Web page: https://patentgrep.com/patent/US9427426B2

## CPC

- A61K 31/381: having five-membered rings
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61P 29/02: without antiinflammatory effect
- A61P 39/02: Antidotes
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Indication of use of erdosteine as antidote in a large number of intoxications, especially in heavy metals like lead or mercury, and paracetamol. Indication of use of erdosteine as prophylaxis for intoxications. Erdosteine can be administered per os or intravenous, using a solution obtained with sodium hydrogen carbonate and bidistilled water.

## Claims

### Claim 1

A method of antidote treatment of lead intoxication or mercury intoxication comprising administering an effective amount of erdosteine to a patient in need thereof, thereby treating said patient of said lead intoxication or of said mercury intoxication.

### Claim 2 (depends on 1)

The method according to claim 1, wherein erdosteine is in injectable form.

### Claim 3 (depends on 1)

The method according to claim 1, wherein erdosteine is in oral formulation.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the injectable formulation comprises erdosteine and sodium hydrogen carbonate in a molar ratio ranging from 1:2 to 2:1.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the injectable formulation comprises erdosteine and sodium hydrogen carbonate in a molar ratio of 1:1.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the injectable formulation has a composition including 350 mg erdosteine and 118 mg sodium hydrogen carbonate in 2 m bidistilled water.

### Claim 7 (depends on 5)

The method according to claim 5, wherein the injectable formulation contains 175 mg erdosteine and 59 mg sodium hydrogen carbonate in 10 ml bidistilled water; or 350 mg erdosteine and 118 mg sodium hydrogen carbonate in 10 ml bidistilled water.